Janot François, de Raucourt Dominique, Benhamou Ellen, Ferron Christophe, Dolivet Gilles, Bensadoun René-Jean, Hamoir Marc, Géry Bernard, Julieron Morbize, Castaing Marine, Bardet Etienne, Grégoire Vincent, Bourhis Jean
Institut Gustave-Roussy, 39 rue Camille Desmoulins, Villejuif, France.
J Clin Oncol. 2008 Dec 1;26(34):5518-23. doi: 10.1200/JCO.2007.15.0102. Epub 2008 Oct 20.
Full-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity. The Groupe d'Etude des Tumeurs de la Tête et du Cou and Groupe d'Oncologie Radiothérapie Tête Et Cou groups performed a randomized study to assess its efficacy.
Between 1999 and 2005, 130 patients with head and neck cancer were treated with salvage surgery and randomly assigned to full-dose reirradiation combined with chemotherapy (RT arm) or to observation (a "wait and see" approach; WS arm). Eligibility criteria were recurrence or a second primary tumor in a previously irradiated area, no major sequelae resulting from the first radiotherapy, good general condition, no distant metastasis, and salvage surgery with macroscopic complete resection. Patients in the RT arm received 60 Gy over 11 weeks combined with concomitant fluorouracil and hydroxyurea.
Sixty-five patients were randomly assigned to each arm. There was no imbalance in the distribution of the main tumor and patients characteristics. The most serious acute toxicity in the RT arm was mucositis, attaining grade 3 or 4 in 28% of patients. At 2 years, 39% of patients in the RT arm and 10% in the WS arm experienced grade 3 or 4 late toxicity according to Radiation Therapy Oncology Group criteria (P = .06). Disease-free survival (DFS) was significantly improved in the RT arm, with a hazard ratio of 1.68 (95% CI, 1.13 to 2.50; P = .01), but overall survival (OS) was not statistically different.
Full-dose reirradiation combined with chemotherapy after salvage surgery significantly improved DFS, but had no significant impact on OS. An increase in both acute and late toxicity was observed.
全剂量再程放疗联合化疗已被证明在挽救性手术后是可行的,且毒性可接受。头颈肿瘤研究组(Groupe d'Etude des Tumeurs de la Tête et du Cou)和头颈放疗肿瘤学组(Groupe d'Oncologie Radiothérapie Tête Et Cou)进行了一项随机研究以评估其疗效。
1999年至2005年间,130例头颈癌患者接受了挽救性手术,并随机分为全剂量再程放疗联合化疗组(放疗组)或观察组(“观察等待”方法;观察组)。入选标准为先前照射区域复发或出现第二原发性肿瘤、首次放疗无严重后遗症、一般状况良好、无远处转移以及挽救性手术实现宏观完全切除。放疗组患者在11周内接受60 Gy放疗,并同时给予氟尿嘧啶和羟基脲。
每组随机分配65例患者。主要肿瘤和患者特征分布无失衡。放疗组最严重的急性毒性是黏膜炎,28%的患者达到3级或4级。根据放射治疗肿瘤学组标准,2年时,放疗组39%的患者和观察组10%的患者出现3级或4级晚期毒性(P = 0.06)。放疗组无病生存期(DFS)显著改善,风险比为1.68(95% CI,1.13至2.50;P = 0.01),但总生存期(OS)无统计学差异。
挽救性手术后全剂量再程放疗联合化疗显著改善了DFS,但对OS无显著影响。观察到急性和晚期毒性均增加。